Investigating Targeted CD3 Activation in Cytotoxic T cells via Immune Checkpoint Inhibition from thescientistllc on Vimeo.

Immune checkpoint inhibitors promote anti-tumor immune responses by enhancing T-cell activity. Measuring the pharmacodynamic effects of these drug types presents a challenge as both the immune and cancer cell populations must be separated and assessed individually. Using a quantitative multiplex immunofluorescence assay (mIF) allows for in-depth cell phenotype characterization and spatial context. Researchers at Frederick National Laboratory for Cancer Research developed a robust mIF assay with InSituPlex® technology to better investigate T-cell activation states within the tumor microenvironment and across multiple patient tumor biopsies.

In this webinar, Dr. Kristin Fino of the Frederick National Laboratory will present the obstacles associated with developing biomarker strategies and a multiplex immunofluorescence solution that improved the assessment of tumor-immune interactions.

This webinar is sponsored by Ultivue Inc.

Topics to be covered:

  • Introduction to the InSItuPlex® technology
  • Development...

Meet the Speaker:

Sean Downing, PhD, MBA 
Director, Customer Engagement

Kristin Fino, PhD


Leidos Biomedical NCI Frederick

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!